Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oncology.

× No keyword cloud information.

30 in total

1. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

Authors: W M Gregory; M A Richards; J S Malpas
Journal: J Clin Oncol Date: 1992-02 Impact factor: 44.544

2. A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors: E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal: Cancer Date: 1973-08 Impact factor: 6.860

3. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors: F P Li; J F Fraumeni
Journal: Ann Intern Med Date: 1969-10 Impact factor: 25.391

Review 4. Retinoids in cancer therapy.

Authors: M A Smith; D R Parkinson; B D Cheson; M A Friedman
Journal: J Clin Oncol Date: 1992-05 Impact factor: 44.544

5. Functional myocardial impairment in children treated with anthracyclines for cancer.

Authors: S T Yeung; C Yoong; J Spink; A Galbraith; P J Smith
Journal: Lancet Date: 1991-04-06 Impact factor: 79.321

6. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

Authors: D D Von Hoff; M Rozencweig; M Layard; M Slavik; F M Muggia
Journal: Am J Med Date: 1977-02 Impact factor: 4.965

7. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.

Authors: I C MacLennan; C Chapman; J Dunn; K Kelly
Journal: Lancet Date: 1992-01-25 Impact factor: 79.321

Review 8. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors:
Journal: Lancet Date: 1992-01-04 Impact factor: 79.321

9. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

Authors: J Muindi; S R Frankel; W H Miller; A Jakubowski; D A Scheinberg; C W Young; E Dmitrovsky; R P Warrell
Journal: Blood Date: 1992-01-15 Impact factor: 22.113

10. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.

Authors: P W Johnson; P I Thompson; M T Seymour; N P Deasy; R C Thuraisingham; M L Slevin; P F Wrigley
Journal: Br J Cancer Date: 1991-09 Impact factor: 7.640